Recorded history of LL-37 — FDA records, PCAC review history, and state overlays. Each entry links to its source; entries marked reported rest on reported sources; source classification alone does not authenticate a vote tally.
Planned review
Eligibility not established here
FDA intends to review LL-37 at a further Pharmacy Compounding Advisory Committee meeting — by the end of February 2027 (exact date not yet posted). FDA PCAC ↗
We do not sell, source, or supply LL-37. This is a monitoring record from public government sources — not a product, and not advice.
Federal history
No MSR event recorded in the published federal history for LL-37. This is a gap in this tracker’s record, not evidence that no federal position or source exists.
State overlays
No MSR event recorded in the published state history for LL-37. State boards hold independent authority; legislation is monitored via LegiScan and board positions are added as they are verified.
Track LL-37 changes
Get the free weekly Brief — FDA and state moves on peptide & GLP-1 compounding, with the source and the date. Members are alerted for their states as soon as a change is published.
